Amcinonide
(Synonyms: 安西奈德; CL-34699) 目录号 : GC42782
A synthetic corticosteroid
Cas No.:51022-69-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Amcinonide inhibit NO release from activated microglia with IC50 3.38 nM. Amcinonide has affinity for the glucocorticoid receptor.IC50 value: 3.38 nM [1]Target: NO releasein vitro: Simultaneous immunofluorescent staining for T6 and Ia antigenicity within human epidermis of Amcinonide treated skin detected reduced numbers of T6+/Ia+ cells with a concomitant increase in T6+/Ia- cells. [2]in vivo: Amcinonide is an anti-inflammatory agent, elicites whitening of a few hairs in both pheomelanic and eumelanic mice. Amcinonide brings about a marked reduction in the numbers of DOPA-positive epidermal melanocytes inhabiting the tails of eumelanic or pheomelanic mice. Amcinonide exertes a deleterious influence on the structure and function of tail epidermis. [3]
References:
[1]. Hong J, et al. Identification and characterization of triamcinolone acetonide, a microglial-activation inhibitor. Immunopharmacol Immunotoxicol. 2012 Dec;34(6):912-918.
[2]. Berman B, et al. Modulation of expression of epidermal Langerhans cell properties following in situ exposure to glucocorticosteroids. J Invest Dermatol. 1983 Mar;80(3):168-171.
[3]. Quevedo WC Jr, et al. Influence of depigmenting chemical agents on hair and skin color in yellow (pheomelanic) and black (eumelanic) mice. Pigment Cell Res.1990 Mar-Apr;3(2):71-79.
| Cas No. | 51022-69-6 | SDF | |
| 别名 | 安西奈德; CL-34699 | ||
| Canonical SMILES | O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@]2(F)[C@@H](O)C[C@@]4(C)[C@@]3([H])C[C@]5([H])[C@@]4(C(COC(C)=O)=O)OC6(CCCC6)O5)=C1 | ||
| 分子式 | C28H35FO7 | 分子量 | 502.6 |
| 溶解度 | DMF: 20 mg/ml,DMSO: 25 mg/ml,DMSO:PBS(pH7.2) (1:1): 0.5 mg/ml,Ethanol: 10 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9897 mL | 9.9483 mL | 19.8965 mL |
| 5 mM | 0.3979 mL | 1.9897 mL | 3.9793 mL |
| 10 mM | 0.199 mL | 0.9948 mL | 1.9897 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Allergic contact dermatitis from Amcinonide
Contact Dermatitis 1985 Apr;12(4):213-4.PMID:3160532DOI:10.1111/j.1600-0536.1985.tb01109.x.
Allergic contact dermatitis from topical corticosteroids has been regarded as rare. However, it should be considered in long-standing, resistant or worsening eczema in spite of topical steroid therapy. Cases of allergic dermatitis from Amcinonide have been reported previously. We report an additional case.
Investigations on the development and regression of corticosteroid-induced thinning of the skin in various parts of the human body during and after topical application of Amcinonide
Dermatologica 1989;178(2):93-7.PMID:2924987DOI:10.1159/000248399.
In 15 subjects 6 different parts of the body were treated with the potent topical corticosteroid (CS) Amcinonide once a day for 21 days. The skin thickness of the treated areas was measured sonographically at intervals of 2 days. After completion of the CS application the regression of the CS-induced reduction in skin thickness was measured for a further 14 days. A clear thinning of the skin could be measured after only 4 days and continued up to the 21st day of treatment. This thinning regressed completely in all areas after 10-12 days. The thinning and regression curves were very similar for all body areas. Differences in intensity of thinning were evident. No tachyphylaxis was detected.
A comparative study of Amcinonide and halcinonide in the treatment of eczematous dermatitis
Cutis 1984 Aug;34(2):190-4.PMID:6383735doi
Thirty-three patients with acute or subacute eczematous dermatitis were treated for two weeks in a double-blind, parallel-group study to compare the efficacy and cosmetic acceptability of 0.1 percent Amcinonide cream and 0.1 percent halcinonide cream. Patients in both treatment groups showed significant (p less than 0.05) improvement from baseline for most signs and symptoms at the three evaluation times (days 3, 7, and 14). Comparisons between groups showed no significant differences at any evaluation except at day 14, when the amicinonide-treated patients had significantly (p = 0.04) less edema. The physician's evaluations were not significantly different except at day 7, when the halcinonide patients showed significantly (p = 0.04) more overall improvement. The patients' overall evaluations were not significantly different at any time. In general, both creams were cosmetically acceptable. At day 3, seven Amcinonide patients noted skin tightening compared to one halcinonide patient; four halcinonide patients (as well as two at day 7 and one at day 14) reported stinging compared to only one Amcinonide patient. In addition, two halcinonide patients reported a burning sensation at one or more evaluations compared to no such reports from Amcinonide patients. One other side effect, a metallic taste in the mouth, occurred in a halcinonide-treated patient.
Amcinonide vs. betamethasone dipropionate ointments in the treatment of psoriasis
Cutis 1985 May;35(5):489-92.PMID:3891239doi
A randomized, double-blind study compared the efficacy and safety of Amcinonide and betamethasone dipropionate ointments, applied twice daily for two weeks, in the treatment of patients with moderate to severe psoriasis. Thirty-four patients were enrolled; thirty patients had had psoriasis for more than one year, and in the majority of patients, it was stable or slowly exacerbating. Significant improvement from baseline was observed with both ointments at weeks 1 and 2. The two drugs showed comparable cosmetic acceptability. Adverse cutaneous symptoms experienced were burning (both groups), itching (Amcinonide), and stinging (beta-methasone); no serious adverse effects were reported.
Management of eczematous dermatitis with Amcinonide or betamethasone valerate. A double-blind comparative study
Cutis 1979 Dec;24(6):642-5.PMID:391500doi
A new topical corticosteroid formulation, 0.1 percent Amcinonide cream, was compared with 0.1 percent betamethasone valerate cream in a double-blind, parallel study of the management of eczematous dermatitis. Both treatment groups showed statistically significant improvement in most symptoms and in overall disease status after one and two weeks of treatment. The Amcinonide group had greater improvement in individual symptoms and significantly greater overall improvement than did the betamethasone valerate group. Side effects were few and minor in both groups. The Amcinonide cream was found to be both safe and effective for the management of eczematous dermatitis.